Modeling Cardiovascular Diseases with Cardiomyocytes

Cardiomyocytes play a critical role in the in vitro study of cardiovascular diseases. Ace Therapeutics aims to provide a wide range of cardiomyocyte cell lines and induced pluripotent stem cell-derived cardiomyocytes to advance basic research and therapeutic development of cardiovascular diseases.

Applications of Cardiomyocytes in Cardiovascular Disease Research

Cardiomyocytes can be used as research models for cardiovascular diseases, helping gain insight into the pathophysiological mechanisms and elucidate the potential etiology of cardiovascular diseases.

• In Vitro Research Models for Cardiovascular Diseases
  Cardiomyocytes can be used to better study the pathogenesis of cardiovascular disease while reducing the use of animal models, ethical controversies, and experimental costs.
• Cardiovascular Drug Screening & Testing
  High-throughput screening with cardiomyocytes allows rapid assessment of the effects of a large number of compounds on cardiomyocyte function, which can be used to identify potential drug candidates of cardiovascular diseases.
• Stem Cell-based Therapy for Cardiovascular Diseases
  Cardiomyocytes can be utilized in stem cell-based therapy for cardiovascular diseases. By differentiating induced pluripotent stem cells (iPSCs) into cardiomyocytes in vitro to promote repair and regeneration of damaged cardiac tissue.

Fig. 1 Generation of iPSC cardiomyocytes to cardiovascular diseases. (Funakoshi S. and Yoshida Y., 2021)

Ace Therapeutics can provide a variety types of cardiomyocytes and induced multifunctional stem cell development services, aiming to help our clients advance basic research and therapeutic development of cardiovascular diseases.

Ace Therapeutics is a contract research organization dedicated to providing R&D outsourcing services for cardiovascular disease research. We provide our clients with cardiomyocytes to fully support in vitro research of cardiovascular diseases. If you are interested in our services, please do not hesitate to contact us.

1. Funakoshi, S.; Yoshida Y. Recent progress of iPSC technology in cardiac diseases. Arch Toxicol. 2021, 95(12):3633-3650.